Money Thrill commented on a stock · Jan 8 21:11

European Morning News, Novo Nordisk and Valo Health [CercleFinance]

$Novo-Nordisk A/S (NVO.US)$ and Valo Health announce an expansion of their collaboration to discover and develop innovative treatments for obesity, type 2 diabetes and cardiovascular diseases, leveraging Valo’s artificial intelligence and human data. The initial agreement, signed in September 2023, included up to 11 therapeutic programs and potential payments of $2.7 billion.

The expanded agreement now includes up to 20 programs, with potential payments of $4.6 billion, an initial investment of $190 million, and an increased focus on obesity and diabetes. The companies will use Valo’s Opal platform and their respective expertise to identify and develop innovative treatments for obesity, type 2 diabetes and cardiovascular diseases. [NFA]

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

23K Views

Comment

Money Thrill OP : Novo Nordisk climbed more than "3% in Copenhagen", following an upgrade of the pharmaceutical company's advice from 'neutral' to 'BUY', despite a sharply lowered target price from 1,100 to 750 Danish crowns. The broker lowered its target after CagriSema, but judged the wave of selling on the stock to be exaggerated. 'Novo remains the most exciting growth story in the EU pharmaceutical industry and is now reasonably valued,' it judges.

Report
Reply

Cancel Reply

Money Thrill

Retired investment advisor & Dr.

316

Followers

Following

1418

Visitors